AARON DOHENY: Open Payments
NPI 1730532854 · ST PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,632 in 154 payments from 42 companies in 2025. Trend: 2023 $3,079 · 2024 $4,768 · 2025 $3,632
Food & beverage: $3,549Long term medical supply or device loan: $83
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 16 | $403 |
| Janssen Biotech, Inc. | 18 | $377 |
| Daiichi Sankyo Inc. | 10 | $279 |
| PFIZER INC. | 8 | $189 |
| Merck Sharp & Dohme LLC | 7 | $169 |
| Celgene Corporation | 8 | $147 |
| Gilead Sciences, Inc. | 7 | $135 |
| Incyte Corporation | 5 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $123 |
| ABBVIE INC. | 5 | $117 |
Products named: KISQALI, Enhertu, REBLOZYL, KEYTRUDA, Trodelvy, LUTATHERA, TALVEY, Orserdu.
Industry payments across FL — which companies pay providers there.
